New Targeted Therapies in Myelodysplastic Syndrome: The Role of Farnesyltransferase and Proteasome Inhibitors

BMC Proceedings - United Kingdom
doi 10.1186/1753-6561-4-s2-p44
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Resistance to Proteasome Inhibitors and Other Targeted Therapies in Myeloma

British Journal of Haematology
Hematology
2018English

Farnesyltransferase Inhibitors: A New Class of Cancer Chemotherapeutics

Biochemical Society Transactions
Biochemistry
1996English

Updates on the Role of Adrenal Steroidogenesis Inhibitors in Cushing’s Syndrome: A Focus on Novel Therapies

Pituitary
EndocrinologyMetabolismDiabetes
2016English

The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics

Annual Review of Pharmacology and Toxicology
ToxicologyPharmacology
1997English

New Targeted Therapies in Spondyloarthritis: What Are the Limits?

Immunotherapy
OncologyAllergyImmunology
2019English

Developments in the Treatment of Transfusion-Dependent Anemia in Patients With Myelodysplastic Syndromes: Epidemiology, Etiology, Genetics, and Targeted Therapies

Advances in Genomics and Genetics
2014English

Design, Synthesis, and Biological Evaluation of Bone-Targeted Proteasome Inhibitors for Multiple Myeloma

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2013English

Emerging Therapies for the Myelodysplastic Syndromes

Clinical Hematology International
2019English

A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy